Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04740333 |
| Other study ID # |
0384-20-MMC |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2023 |
| Est. completion date |
February 1, 2024 |
Study information
| Verified date |
March 2024 |
| Source |
Meir Medical Center |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU)
worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1).
Sepsis causes an extreme physiological stress response, with significant changes in
metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to
hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are
associated with increased mortality (3). In critically-ill patients, the glucose threshold
from which damage may be caused remains controversial.
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those
who were not diabetic before, for several reasons. Sepsis causes massive activation of
anti-inflammatory mediators which enhances the activity of counter-regulatory hormones,
including cortisol, glucagon and catecholamines. Those hormones increase both hepatic
gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of
hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable
state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis
and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and
morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood
glucose level at ICU admission was found to be a poor prognostic factor at various studies on
different ICU patient populations (7-9). For example, in ICU patients admitted due to acute
myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high
blood glucose levels at admission, even in non-diabetic patients, were associated with both
increased in- hospital and long-term mortality (7). Among patients admitted due to acute
heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and
non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies
within one year of admission (8). Among non-diabetic patients admitted to the hospital due to
acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with
a significant increase in all-causes in-hospital mortality (9). However, there is currently
insufficient information regarding the prognostic impact of high admission glucose levels of
non-diabetic septic patients admitted to the ICU (10).
Description:
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU)
worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1).
Sepsis causes an extreme physiological stress response, with significant changes in
metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to
hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are
associated with increased mortality (3). In critically-ill patients, the glucose threshold
from which damage may be caused remains controversial.
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those
who were not diabetic before, for several reasons. Sepsis causes massive activation of
anti-inflammatory mediators which enhances the activity of counter-regulatory hormones,
including cortisol, glucagon and catecholamines. Those hormones increase both hepatic
gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of
hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable
state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis
and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and
morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood
glucose level at ICU admission was found to be a poor prognostic factor at various studies on
different ICU patient populations (7-9). For example, in ICU patients admitted due to acute
myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high
blood glucose levels at admission, even in non-diabetic patients, were associated with both
increased in- hospital and long-term mortality (7). Among patients admitted due to acute
heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and
non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies
within one year of admission (8). Among non-diabetic patients admitted to the hospital due to
acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with
a significant increase in all-causes in-hospital mortality (9). However, there is currently
insufficient information regarding the prognostic impact of high admission glucose levels of
non-diabetic septic patients admitted to the ICU (10).
Outcomes:
Main outcome: To study the correlation between high blood glucose levels (above 180 mg / dL)
upon ICU admission of non-diabetic patients with sepsis, and 28-day mortality, compared to
ICU admitted septic patients with normal blood glucose levels upon admission (less than 180
mg / dL and above 70 mg / dL).
Secondary outcomes: To study the correlation between high blood glucose levels (above 180 mg
/ dL) upon ICU admission of non-diabetic patients with sepsis, and morbidity parameters, such
as ventilation days, vasopressor and inotropic support, need for dialysis, need for
tracheostomy, APACHE-2 score and admission lactate level compared to ICU admitted septic
patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70
mg / dL).
Materials and methods:
Study design: Cohort retrospective study. Study population: Non-diabetic patients aged 18-99
who were admitted to the ICU between 1.1.2014 and 30.1.2020 due to sepsis or septic shock.
Study groups: Group A - Patients with admission blood glucose level lower than 180 mg / dL
(but higher than 70 mg / dL).
Group B- Patients with admission blood glucose level higher than 180 mg / dL. Inclusion
criteria: 1. Patients admitted to the ICU between 1.1.2014-30.1.2020. 2. Diagnosis of sepsis
or septic shock upon admission. 3. Age over 18 years. 4. No previous diagnosis of diabetes
mellitus. Exclusion criteria: 1. Patients with prior diagnosis of diabetes mellitus. 2.
Admission hypoglycemia (blood glucose levels below 70 mg / dL). 3. Patients who were given
insulin or intravenous glucose before the first ICU blood glucose measured level.
Data collection: Observational data collection format from hospital files and computerized
systems (Chameleon system and iMDsoft software).
Data to be collected: age, gender, ICU and hospital admission times, source of infection,
ventilation days, pressor or inotropic support, 28-day mortality, past medical history
including regular medications, APACHE-2 score, admission lactate level, need for dialysis and
need for tracheostomy.
Study group size: 1000 patients. Statistical analysis: All the parameters will be
statistically examined by a qualified statistician depending on the type of data. We will use
the Chi square test to analyze the individual data and the Mann-Whitney test to analyze the
continuous data.
